Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion

British Journal of Ophthalmology

Volumn 92, Issue 3, 2008, Pages 351-355

  Kreutzer, T C ^a   Alge, C S ^a   Wolf, A H ^a   Kook, D ^a   Burger, J ^a   Strauss, R ^a   Kunze, C ^b   Haritoglou, C ^a   Kampik, A ^a   Priglinger, S G ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; TREATMENT DURATION; TREATMENT OUTCOME; VISION; VISUAL ACUITY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOVEA CENTRALIS; HUMANS; INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RETINAL VEIN OCCLUSION; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 40549120630     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2007.123513     Document Type: Article

References (19)

1. The Eye Disease Case-control Study Group. Risk factors for branch retinal vein occlusion. Am J Ophthalmol 1993;116:286-96.
2. Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol 1984;98:271-82.
3. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 2007;27:141-9.
4. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006;26:275-8.
5. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006;26:279-84.
6. Vinores SA, Xiao WH. Aslam S, et al. Implication of the hypoxia response element of the VEGF promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development. J Cell Physiol 2006;206:749-58.
7. Boyd SR, Zachary I, Chakravarthy U, et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol 2002;120:1644-50.
8. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989;246:1309-12.
9. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-9.
10. 2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 1990;50:1774-8.
11. Spandau U, Wickenhauser A, Rensch F, et al. Intravitreal bevacizumab for branch retinal vein occlusion. Acta Ophthalmol Scand 2007;85:118-19.
12. Ferris FL 3rd, Kassoff A, Bresnick GH, et al. New visual acuity charts for clinical research. Am J Ophthalmol 1982;94:91-6.
13. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-9.
14. Rabena MD, Pieramici DJ, Castellarin AA, et al. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 2007;27:419-25.
15. Pai SA, Shetty R, Vijayan PB, et al. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 2007;143:601-6.
16. Priglinger SG, Wolf AH, Kreutzer TC, et al. Intravitreal bevacizumab for central retinal vein occlusion: six month results of a prospective trial. Retina 2007;8:1004-12.
17. Parodi MB, Spasse S, Iacono P, et al. Subthreshold grid laser treatment of macular edema secondary to branch retinal vein occlusion with micropulse infrared (810 nanometer) diode laser. Ophthalmology 2006;113:2237-42.
18. Battaglia Parodi M, Saviano S, et al. Grid laser treatment in macular branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 1999;237:1024-7.
19. Barbazetto IA, Schmidt-Erfurth UM. Evaluation of functional defects in branch retinal vein occlusion before and after laser treatment with scanning laser perimetry. Ophthalmology 2000;107:1089-98.